Compare ADMA Biologics Inc (ADMA) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while C.H. Robinson Worldwide, Inc. trades at $144.86 (market cap $17.33B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 7.9× ADMA Biologics Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.7% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CHRW | |
|---|---|---|
Market Cap | $2.18B | $17.33B |
Sector | Health | Industrials |
52-Week High | $20.38 | $209.42 |
52-Week Low | $7.60 | $118.77 |
Enterprise Value | $2.25B | $19.15B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
C.H. Robinson Worldwide (CHRW) trades at $149.35, up 1.83% on the day, with a bearish technical signal from moving averages but strong profitability metrics including a 37.12% ROE. Recent Q2 2026 earnings beat expectations with EPS of $1.61 versus $1.53 estimated, driven by pricing and efficiency gains. The stock shows support near $146 and resistance at $152, with a consensus analyst price target of $196.00 implying significant upside potential from current levels.
The outlook remains positive based on consistent earnings beats and solid fundamentals, though risks include soft freight demand and rising costs. Analyst sentiment is moderately bullish with 48% buy ratings, but investors should monitor competitive pressures and macroeconomic headwinds that could impact logistics sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
